<DOC>
	<DOCNO>NCT02011451</DOCNO>
	<brief_summary>The hypothesis 95 % pure EGCG protect brain cell patient Multiple Sclerosis . To test hypothesis go compare change n-Acetyl-Aspartate ( chemical reflect number neuron metabolism ) one six people MS treat EGCG dose 400mg twice day people MS treat match sugar pill .</brief_summary>
	<brief_title>Safety Brain Protection Effects Green Tea Extract Theaphenon 95 % ( 95 % Pure EGCG ) Multiple Sclerosis</brief_title>
	<detailed_description>This double blind placebo control trial Theaphenon 95 % ( 95 % pure Epigallo-catechin-galleate [ EGCG ] ) treatment MS . The primary outcome change N-Acety-Aspartate ( NAA ) level six month . Secondary outcome change brain atrophy six month . As exploratory outcome correlate change NAA level free Plasma level EGCG 8 hour morning dose . Exploratory outcome include disability progression Expanded Disability Status Scale ( EDSS ) , multiple sclerosis functional composite component cognitive test battery .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis MS McDonald criterion Relapsingremitting MS secondary progressive MS Stable therapy Copaxone , Rebif , Betaseron Avonex 30 mcg least six month EDSS Score less equal 7.0 Ages 1860 . Participants must normal organ marrow function define : Leukocytes ≥3,000/µL Absolute neutrophil count ≥1,500/µL Platelets ≥100,000/µL Total bilirubin ≤local upper limit normal AST ( SGOT ) ≤local upper limit normal ALT ( SGPT ) ≤local upper limit normal Creatinine ≤local upper limit normal MS relapse within 30 day prior enrollment A primary progressive form MS . Previous treatment prior study entry follow : complete radiation ablation bone marrow antiCD4 antibody treatment ( Campath ) time ; mitoxantrone , cyclophosphamide , Natalizumab immunomodulatory immunosuppressant therapy except DMT 's included inclusion criterion methylprednisone relapse within prior nine month . History renal liver disease . Consumption green tea supplement contain green tea tea extract within 30 day prior enrollment . Participants may participate clinical trial involve investigational agent study , within six month prior enrol study . History allergic reaction attribute compound similar chemical biologic composition Polyphenon E , tea , inactive ingredient present active placebo capsule , include gelatin . History allergic reaction gadolinium condition contraindicate MRI . Uncontrolled , clinicallyrelevant active illness ( aside MS ) include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Any condition would make subject , opinion investigator , unsuitable study Inability complete baseline MRI scan Pregnant woman Any underlying predisposition gastrointestinal bleeding ( peptic ulcer disease , gastritis , diverticulitis , colitis , hemorrhoid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Green Tea</keyword>
	<keyword>ECGC</keyword>
	<keyword>Theaphenon</keyword>
	<keyword>Randomized placebo control trial</keyword>
	<keyword>NAA</keyword>
	<keyword>Spectroscopy</keyword>
	<keyword>Brain Atrophy</keyword>
	<keyword>SIENA</keyword>
</DOC>